Summary: Researchers have shown that BA-101, an experimental compound, can strip away a key defensive mechanism used by glioblastoma. By selectively inhibiting the neuronal nitric oxide synthase (nNOS) enzyme that drives excessive nitric oxide production, BA-101 dismantles the tumor’s nitrosative stress shield. In preclinical models this restores sensitivity to temozolomide, slows tumor growth, and promotes targeted cancer cell death.
Key Facts
- Targeting nitrosative stress: Many drug-resistant glioblastoma tumors rely on elevated nitrosative stress. Overproduction of nitric oxide creates a protective chemical environment that supports tumor survival, invasion, and resistance to chemotherapy.
- nNOS blockade mechanism: BA-101 is a selective inhibitor of neuronal nitric oxide synthase (nNOS), the enzyme primarily responsible for producing the excess nitric oxide that fuels this protective state.
- Dismantling malignancy: In cell-based experiments, BA-101 reduced proliferation, impaired migration and invasion, lowered biochemical markers of nitrosative stress, and increased apoptotic cell death in resistant glioblastoma cells.
- Synergy with temozolomide: Combining BA-101 with the standard chemotherapy temozolomide produced a markedly stronger anti-cancer effect than either agent alone, restoring chemosensitivity in resistant cells.
- In vivo efficacy: In preclinical mouse models bearing aggressive glioblastoma xenografts, the combination of BA-101 and temozolomide delivered significantly greater tumor shrinkage and growth suppression than temozolomide alone.
- New combination strategy: Rather than replacing existing chemotherapy, this approach proposes a helper compound designed to dismantle specific tumor survival mechanisms and thereby extend the utility of standard treatments.
Source: Hebrew University of Jerusalem
Research team: The study was led by Postdoctoral Fellow Dr. Mallikar Nimgampalle and Professor Haitham Amal of the Hebrew University of Jerusalem, with additional contributors from the Institute for Drug Research. Their work addresses a central obstacle in glioblastoma care: acquired and intrinsic resistance to temozolomide chemotherapy.
Published in Cancer Medicine, the study demonstrates that BA-101 can resensitize temozolomide-resistant glioblastoma cells to chemotherapy, producing substantial reductions in tumor growth in laboratory and animal models.
Glioblastoma remains one of the most difficult brain cancers to treat. Current standards—surgery, radiation, and temozolomide—often fail because tumors adapt quickly and develop resistance. The new work targets a biochemical escape route tumors use: nitrosative stress driven by overactive nNOS.
By blocking nNOS with BA-101, researchers reduced the biochemical signals that protect cancer cells from damage. Treated cells slowed their growth, lost their invasive and migratory capacity, showed lower nitrosative stress markers, and underwent programmed cell death. Crucially, when BA-101 was combined with temozolomide, tumor responses improved substantially compared with chemotherapy alone, including in mouse xenograft models.
“Temozolomide resistance remains one of the biggest obstacles in treating glioblastoma,” said Prof. Haitham Amal. “Our findings suggest that targeting nitrosative stress can restore the tumor’s sensitivity to treatment. While further studies are required before clinical use, these results point to a promising pathway for more effective therapies against this aggressive cancer.”
The team frames BA-101 not as a replacement for existing chemotherapy but as a chemosensitizer: a companion drug that neutralizes a tumor’s protective chemistry and enables temozolomide to work more effectively. Because the compound targets a mechanism that supports survival under chemotherapy, it may also slow or delay the emergence of further resistance.
BA-101 is currently an experimental agent. The compound was licensed from the Hebrew University of Jerusalem’s technology transfer office and is being advanced by NeuroNOS, a biotechnology company cofounded by Prof. Amal, which aims to move BA-101 from preclinical studies into formal drug development and clinical testing.
Key Questions Answered:
A: Glioblastoma cells can adapt to chemotherapy by increasing nNOS expression and producing large amounts of nitric oxide. This creates nitrosative stress that protects tumor cells, helps them repair DNA damage, and allows them to survive and spread despite treatment, rendering temozolomide less effective.
A: BA-101 selectively inhibits neuronal nitric oxide synthase (nNOS), blocking the tumor’s ability to produce excessive nitric oxide. Without that chemical shield, cancer cells become less stable, lose migratory and invasive capacity, and their internal defenses fall, allowing temozolomide to damage cancer cell DNA more effectively.
A: BA-101 remains in preclinical development. The research team and company partners must complete further safety testing and regulatory work before human trials begin. That pathway can take several years, but the findings provide a clear preclinical rationale for pursuing clinical evaluation.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by staff.
About this brain cancer research news
Author: Danae Marx
Source: Hebrew University of Jerusalem
Contact: Danae Marx – Hebrew University of Jerusalem
Image: Image credit: Neuroscience News
Original Research: Open access. “Targeting Temozolomide-Resistant Glioblastoma: Therapeutic Potential of Neuronal Nitric Oxide Synthase Inhibitor” by Mallikarjuna Nimgampalle, Shashank Kumar Ojha, Maryam Kartawy, Michelle Feivelson, Haitham Amal. Cancer Medicine. DOI: 10.1002/cam4.72067
Abstract
Targeting Temozolomide-Resistant Glioblastoma: Therapeutic Potential of Neuronal Nitric Oxide Synthase Inhibitor
Background and Purpose
Glioblastoma treatment is limited by both inherent and acquired resistance to temozolomide (TMZ). This study tests a novel strategy to overcome TMZ resistance by applying the neuronal nitric oxide synthase inhibitor BA-101 as monotherapy and as an adjuvant to TMZ, with the goal of enhancing TMZ efficacy and improving outcomes for glioblastoma patients.
Experimental Approach
The investigators used temozolomide-resistant human glioblastoma cell lines (LN-18 and LN-229) to evaluate BA-101’s effects on cell proliferation, invasion, migration, nitrosative stress biomarkers, and apoptosis. Methods included western blot analysis, flow cytometry, Annexin V/PI staining, and in vitro functional assays. An in vivo evaluation used an LN-229 xenograft model in SCID mice to measure tumor response to BA-101 alone and combined with TMZ.
Key Results
BA-101 exhibited notable anti-cancer activity and sensitized resistant glioblastoma cells to temozolomide. The compound reduced nitrosative stress, inhibited clonogenic growth, invasion, and migration, and promoted apoptosis. In SCID mice bearing LN-229 xenografts, BA-101 combined with TMZ produced a significant decrease in tumor volume compared with chemotherapy alone.
Conclusions and Implications
These findings support further preclinical and translational development of BA-101 as a potential anticancer agent and a chemosensitizer to restore temozolomide effectiveness in glioblastoma therapy. Continued safety studies and clinical development will be needed to evaluate its potential benefit in patients.